Dante Labs Announces Expansion of its Finance Team with the Appointment of Andre Nel as Chief Financial Officer, Dalila Rahmani as Chief Accounting Officer, Laura D’Angelo as VP Investor Relations and Omar Elbakshish as Senior Director
September 14 2021 - 7:30AM
Dante Labs, a global leader in genomics and precision medicine,
today announced the appointments of Andre Nel, Dalila Rahmani,
Laura D’Angelo and Omar Elbakshish to the company’s management
team, expanding its global leadership to help scale the growing
business.
“We are thrilled to welcome Andre, Dalila, Laura and Omar to the
expanding leadership team here at Dante,” said Andrea Riposati, CEO
of Dante Labs. “As we work to deliver a more human approach to
healthcare, it is our shared vision of the future and growing
importance genomics is playing in healthcare that will help to meet
the unmet needs of our customers from whole genome sequencing to
drug discovery and development to COVID testing.”
These leaders will join Dante’s finance team to help scale the
business as we work to deliver a global brand of tests and services
resulting in better outcomes for people around the world.
Leading the team, Andre Nel joins Dante Labs as Chief Financial
Officer. Andre brings more than 20 years of experience providing
high-value strategic and operational financial support for global
multibillion-dollar organizations such as Pfizer and Illumina. Most
recently, Andre was the Vice President of Finance at Illumina
(NASDAQ: ILMN) in San Diego.
Dalila joins Dante Labs as the Chief Accounting Officer. Dalila
previously worked with Andre at Illumina as the head of
Controllership and Shared Services for the EMEA region. Dalila has
most recently led the Illumina Commercial Finance team,
specializing in financial forecasting, budgeting, business
partnering and management. Prior to joining Illumina she started
her career as an auditor with Ernst & Young. Dalila has a
demonstrated history working in the biotechnology industry and a
master’s degree focused on Accounting and Finance. Her work in the
industry will benefit us greatly in our more personalized approach
to medicine and healthcare.
Laura D’Angelo joins Dante Labs as Vice President of Investor
Relations. Most recently, Laura was the Head of Investor Relations
at Invitae (NYSE: NVTA), specializing in external communication
targeting analysts, investors and financial media as well as
clinician and patient customers. With a career rooted in
communications, Laura brings a unique perspective to Dante’s
finance team as we turn sequencing data into life-saving answers
for the people we serve.
Omar Elbakshish joins Dante Labs as Senior Director of Business
Finance. Skilled in financial modeling, forecasting and business
partnering, Omar also joins Dante from Illumina. With a
demonstrated history working in finance roles in the biotechnology
industry throughout his career, Omar will help Dante to deploy
genomic applications that have real impact on people’s lives.
“I’m so pleased to be leading this passionate and talented
finance team here at Dante Labs to help accelerate genomics on a
global scale to improve healthcare outcomes,” said Andre Nel, Chief
Financial Officer of Dante Labs. “Having worked previously with
Dalila and Omar and now collaborating with Laura, I’m confident we
have the right team of professionals to achieve our mission and
demonstrate how essential genomics is to a holistic and human
approach to healthcare around the world.”
About Dante LabsDante Labs is a global genomic
data company building and commercializing a new class of
transformative health and longevity applications based on whole
genome sequencing and AI. Our assets include one of the largest
private genome databases with research consent, a proprietary
software platform designed to unleash the power of genomic data at
scale and proprietary processes which enable an industrial approach
to genomic sequencing.
Headquartered in Cambridge, United Kingdom, with
a research laboratory in Wolverhampton, Dante Labs supported the UK
Government’s urgent requirement to scale-up a high-capacity, highly
automated testing solution for Covid-19, including infected
patients as well as those with antibodies. Dante Labs was able to
deliver by leveraging existing technology that had been developed
for whole genome sequencing.
ContactGiorgio Lodimedia@dantelabs.com+39 0862
191 0671www.dantelabs.com
Invitae (NYSE:NVTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Invitae (NYSE:NVTA)
Historical Stock Chart
From Apr 2023 to Apr 2024